Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05186974 · ClinicalTrials.gov registry record · Phase 2
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Gilead Sciences.
- Active
- Registry status
- Phase 2
- Development phase
- 193
- Enrollment target
- 20
- Study locations
NCT05186974: Active Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Gilead Sciences.
NCT05186974 is a Phase 2 study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Gilead Sciences. The registered enrollment target is 193 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05186974, a Phase 2 study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Gilead Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 193 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and its dosing in combination with pembrolizumab or pembrolizumab and a platinum agent (carboplatin or cisplatin), in participants with advanced or metastatic (cancer that has spread) non-small-cell lung cancer (NSCLC).
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Sacituzumab Govitecan-hziy (SG)
Study Locations (20)
California
- Beverly Hills Cancer Center - Beverly Hills
- USC/Norris Comprehensive Cancer Center - Los Angeles
- UCLA Hematology/Oncology - Santa Monica - Los Angeles
- UC Irvine Health - Orange
- Stanford Cancer Institute - Stanford
Illinois
- Northwestern Memorial Hospital - Chicago
- Rush University Medical Center - Chicago
- Orchard Healthcare Research Inc. - Skokie
New York
- Weill Cornell Medical/New York-Presbyterian Hospital - New York
- Great Lakes Cancer Care - Williamsville
North Carolina
- Wake Forest Baptist Health - High Point Medical Center - High Point
- FirstHealth Outpatient Cancer Center - Pinehurst
Alaska
- Alaska Oncology and Hematology, LLC. - Anchorage
Colorado
- University of Colorado Hospital - Anschutz Cancer Pavilion (ACP) - Aurora
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 193 participants |
| Start Date | 2022-05-30 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
What the registry record for NCT05186974 still lists
NCT05186974 is an interventional study that assigns participants to a tested intervention. The registered 193 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT05186974 names 20 study sites across 12 states, led by California, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT05186974 about?
NCT05186974 is a clinical study titled "Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)". The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and its dosing in combination with pembrolizumab or pembrolizumab and a platinum agent (carboplatin or cisplatin), in participants with advanced or metastatic (cancer that has spread) non-small-ce...
What is the current status of trial NCT05186974?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 193 participants. The study started on 2022-05-30. Estimated completion is 2026-09.
What conditions does trial NCT05186974 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT05186974?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Cisplatin (DRUG), Sacituzumab Govitecan-hziy (SG) (DRUG).
Who is sponsoring clinical trial NCT05186974?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05186974 being conducted?
This trial has 20 study locations across Alaska, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05186974's enrollment target sits among peer trials
193 169th of 454 higher than 286 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06226220 · 193 participants · NA
Percutaneous Nerve Evaluation Trial Time
- NCT03593759 · 194 participants · Phase 3
Cardiac Sarcoidosis Randomized Trial
- NCT05053152 · 194 participants · Phase 2
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
- NCT05156112 · 194 participants · NA
OSA PAP Treatment for Veterans With SUD and PTSD on Residential Treatment Unit
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI